5-fluorouracil + doxorubicin + mitomycin C

The combination of 5-fluorouracil, doxorubicin (also known as adriamycin), and mitomycin C—commonly referred to as the FAM regimen—is a multi-agent chemotherapy protocol used primarily in the treatment of advanced cancers such as gastric cancer, pancreatic adenocarcinoma, biliary tract cancer, and hormone-refractory prostate cancer. Each component is a cytotoxic small molecule with distinct mechanisms: - **5-Fluorouracil** is an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis. - **Doxorubicin** is an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II. - **Mitomycin C** acts as an alkylating agent causing cross-linking of DNA strands. This combination exploits different mechanisms to maximize anti-tumor activity. The regimen has demonstrated partial response rates in several solid tumors but is associated with significant toxicities including myelosuppression[1][2][3][4][6].

Other names

5-FU + doxorubicin + mitomycin CFAM regimen5-fluorouracil, adriamycin and mitomycin-C